HDAC9 and cancer: In addition to classical cancer targets, dual- and multi-target inhibitors combining HDAC inhibition with PIM-1, PARP-1, IDO1, or ribonucleotide reductase inhibition have shown synergistic antiproliferative effects and promising in vivo efficacy.